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REPLY
Brodie et al. raise concerns about the choice of reperfusion therapy
for patients with ST-segment elevation myocardial infarction. Our
study (1) examines mortality after primary percutaneous coronary
intervention (PCI) and does not assess the relative benefits of the
competing therapies. Once the decision to perform primary PCI is
made, we believe every reasonable effort should be made to
decrease door-to-balloon time, regardless of risk status of the
patient and regardless of time from symptom onset to presentation.
In this way, our results demonstrate that the “widely held paradigm
regarding the time-sensitivity of reperfusion therapy” applies to all
patients.
Brodie et al. also make the point that the relationship between
door-to-balloon time and mortality may be confounded by quality
of care. Using National Registry of Myocardial Infarction (NRMI)
data, we have found that time to reperfusion is not closely
associated with performance on other quality indicators such as use
of aspirin, beta-blockers, or angiotensin-converting enzyme inhib-
itors (2). Also, to account for any hospital-level confounding, we
used an analytic technique (hierarchical generalized linear model)
that separates hospital-level effects from patient-level effects.
Brodie and colleagues also suggest that door-to-balloon time
may reflect underlying severity of illness, with sicker patients
requiring more evaluation. Certainly, severity of illness is a poten-
tially confounding variable. Our analysis was adjusted for a variety
of important clinical risk factors (30 in all), including age, heart
rate, blood pressure, heart failure class, and previous history of
myocardial infarction, and it retained a statistically significant
relationship between door-to-balloon time and mortality. Patients
requiring procedures such as temporary pacemaker or intra-aortic
balloon pump would likely be accounted for with adjustment for
presentation characteristics.
Another issue concerned the reliability of the time of symptom
onset. Both clinical trials and registries are limited by patient recall.
However, NRMI was designed to collect information about
reperfusion. There is no evidence that the information about
symptom onset time collected in trials or prospective registries is
better than that collected in NRMI. A potentially more important
factor concerning the reliability of the time of symptom onset
could be the nature of the symptoms changing over time. Very
likely, some patients initially experienced symptoms due to non-
occlusive disease or temporarily occlusive disease and presented
with more severe symptoms from a more recent total persistent
occlusion. In that case, the true time from occlusion to reperfusion
could be overestimated. This limitation also is shared by clinical
trials and registries.
Overall, we agree with Brodie et al. that excessive emphasis on
any measure may be unwise, but we believe that our findings merit
appropriate emphasis on the implementation of systems to im-
prove the timeliness of care. Prior studies show marked delays in
the care of many patients that are not explained by appropriate
treatment or severity of illness. We hope that our findings
encourage all practitioners of primary PCI to ensure that prevent-
able delays are avoided in all appropriate patients.
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Degenerative Valve Disease
Caira et al. (1) need to be congratulated for demonstrating the
presence and importance of chondrification and ossification pro-
cesses in degenerative mitral and aortic valve diseases, respectively.
Understanding these biological processes is instrumental in select-
ing therapies that may potentially retard these processes and
improve clinical outcomes. Thinking beyond the mechanical so-
lutions for valvular lesions is akin to the evolution of the thought
process about coronary artery disease 20 years ago when the
biological targets for therapy and prevention were entertained.
There are potentially many molecular or cellular targets for valve
disease modification. Mechanical factors such as shear stress, flow
rate, and blood pressure, which may initiate these biological
processes, are also potentially modifiable.
One can envision that the predominant process in a given valve
may depend on the stage of the valve disease. For example, the
inflammatory process may be more predominant in less stenotic
aortic valves, and fibrosis, cartilage formation, and osseous trans-
formation may be the latter, less modifiable processes. Was this the
observation of the authors? There are also regional differences in
the shear-stress distribution across the valve leaflets, which might
result in different stages of the process in different parts of the
valve. What were the differences in the biochemical and cellular
processes across the extent of the valve leaflets? These may have
implications in terms of timing of therapies and screening process
for the therapies.
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